This product is no longer in stock
Ebetaxel can be used alone or as an adjunct treatment for advance carcinoma of the ovary, metastatic breast cancer that has failed to respond to combination chemotherapy, or for advanced gastric carcinoma. Ebetaxel can be administered after standard doxorubicin-containing combination chemotherapy in the treatment of node-positive breast cancer.
Do not administer Ebetaxel to patients with an initial neutrophil count of less than 1500/mm³.
33% of all patients exhibited mild hypersensitive reactions to Ebetaxel; however, as these were typically skin flush or skin rash, therapeutic treatment was not usually required and discontinuation of Ebetaxel was not warranted. 25% of patients presented with symptoms of infection. Thrombocytopenia occurred in 11% of all patients. 64% of all patients developed anemia. Mild peripheral neuropathy occurred in near 66% of all patients, especially paresthesia. 22% of patients experience hypotension, while 5% experience bradycardia. Nearly half the patients experienced gastrointestinal side effects, including nausea and vomiting (40%) and diarrhea (30%). Mucositis occurred in about 20% of patients, while alopecia was observed in almost all patients.
EBEWE Pharma Ges.m.b.H. Nfg.KG, A-4866 Unterach, Austria
Also known as: Paclitaxel, Taxol, PacliAll, Mitotax, Paclitax NAB, Zuricxel, Nanoxel, Betaxel, Taxeleon, Abraxane, Intaxel, Oncotex, Paclitec, Bristaxol, Sibatax